Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Antimicrobial Agents and Chemotherapy
G W BoswellT J Walsh

Abstract

AmBisome (ABLP) is a unilamellar liposomal preparation of amphotericin B that has demonstrated an improved safety profile compared to conventional amphotericin B. Single- and multiple-dose pharmacokinetics were determined by using noncompartmental methods for rats administered ABLP at 1, 3, 9, and 20 mg/kg/day. The toxicological profile was evaluated following 30 consecutive days of intravenous ABLP administration. Mean plasma amphotericin B concentrations reached 500 and 380 microg/ml (males and females, respectively) following 30 days of ABLP administration at 20 mg/kg. The overall apparent half-life was 11.2+/-4.5 h (males) or 8.7+/-2.2 h (females), and the overall clearance (CL) was 9.4+/-5.5 ml/h/kg (males) or 10.2+/-4.1 ml/h/kg (females). ABLP appears to undergo saturable disposition, resulting in a non-dose-proportional amphotericin B area under the curve and a lower CL at higher doses. Histopathological examination revealed dose-related transitional-cell hyperplasia in the transitional epithelium of the urinary tract (kidney, ureters, and urinary bladder) and moderate hepatocellular necrosis at the 20 mg/kg/day dose. Administration of ABLP in doses of up to 20 mg/kg/day resulted in 100-fold higher plasma amphotericin B ...Continue Reading

References

Oct 1, 1992·Clinical Pharmacokinetics·R JanknegtD J Crommelin
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·G Gregoriadis
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·R T ProffittJ P Adler-Moore
Jun 1, 1993·Journal of Clinical Pharmacy and Therapeutics·C Gates, R J Pinney

❮ Previous
Next ❯

Citations

Feb 21, 2008·The Journal of Antimicrobial Chemotherapy·R EspadaJ J Torrado
Jun 9, 2016·Expert Review of Anti-infective Therapy·Frank P TverdekDimitrios P Kontoyiannis
May 6, 2017·BioMed Research International·Sandra DoßMartin Sauer
Jun 15, 1999·Pharmaceutical Science & Technology Today·I BekerskyI Lawrence
Jun 9, 2019·Expert Opinion on Drug Metabolism & Toxicology·Shyam SundarBhawana Singh
Jun 22, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andreas H GrollRoger J M Brüggemann
Jun 22, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jill Adler-MooreThomas J Walsh
Apr 12, 2005·Applied Microbiology and Biotechnology·A LemkeO Kayser
Apr 29, 2009·The Journal of Antimicrobial Chemotherapy·Pavel GershkovichKishor M Wasan
Feb 9, 2018·Journal of Drug Targeting·Derfogail DelcassianRobert Langer
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·J A Sánchez-BruneteJ J Torrado
Jul 4, 2006·International Journal of Toxicology·Zhihua ZhangJack M Lipman
Aug 14, 1998·Journal of Clinical Pharmacology·G W BoswellI Bekersky
Oct 29, 2004·The Journal of Antimicrobial Chemotherapy·Jill P Adler-MooreRichard T Proffitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2022 Meta ULC. All rights reserved